1. The Status of Adjuvant and Neoadjuvant Melanoma Therapy, New Developments and Upcoming Challenges

   • Henner Stege
   • Maximilian Haist
   • Stephan Grabbe

   Review Article Open access 23 September 2021 Pages: 537 - 552

   

2. Risk of Infection with Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis

   • Fausto Petrelli
   • Anna Maria Morelli
   • Cinzia Solinas

   Original Research Article 05 July 2021 Pages: 553 - 568

   

3. A Phase 1b Trial of Prexasertib in Combination with Standard-of-Care Agents in Advanced or Metastatic Cancer

   • Kathleen N. Moore
   • David S. Hong
   • Johanna C. Bendell

   Original Research Article 24 September 2021 Pages: 569 - 589

   

4. Phase I Study and Pilot Efficacy Analysis of Entinostat, a Novel Histone Deacetylase Inhibitor, in Chinese Postmenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer

   • Jiani Wang
   • Qingyuan Zhang
   • Binghe Xu

   Original Research Article Open access 01 July 2021 Pages: 591 - 599

   

5. Real-World Tumor Response of Palbociclib Plus Letrozole Versus Letrozole for Metastatic Breast Cancer in US Clinical Practice

   • Adam Brufsky
   • Xianchen Liu
   • Rachel M. Layman

   Original Research Article Open access 02 August 2021 Pages: 601 - 611

   

6. Exploring the Impact of Treatment Switching on Overall Survival from the PROfound Study in Homologous Recombination Repair (HRR)-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC)

   • Rachel Evans
   • Neil Hawkins
   • Neeraj Agarwal

   Original Research Article Open access 03 September 2021 Pages: 613 - 623

   

7. Cabozantinib in Pretreated Patients with Metastatic Renal Cell Carcinoma with Sarcomatoid Differentiation: A Real-World Study

   • Matteo Santoni
   • Francesco Massari
   • Nicola Battelli

   Original Research Article 02 August 2021 Pages: 625 - 632

   

8. A Multi-institutional, Retrospective Analysis of Patients with Metastatic Renal Cell Carcinoma to Bone Treated with Combination Ipilimumab and Nivolumab

   • Kunal Desai
   • Landon Brown
   • Moshe C. Ornstein

   Original Research Article 11 August 2021 Pages: 633 - 642

   

9. Impact of Concomitant Cardiovascular Medication on Survival of Metastatic Renal Cell Carcinoma Patients Treated with Sunitinib or Pazopanib in the First Line

   • Ondřej Fiala
   • Pavel Ostašov
   • Tomáš Büchler

   Original Research Article 07 August 2021 Pages: 643 - 652

   

10. Identification of Regorafenib Prognostic Index (REP Index) via Recursive Partitioning Analysis in Patients with Advanced Hepatocellular Carcinoma Receiving Systemic Treatment: A Real-World Multi-Institutional Experience

    • Margherita Rimini
    • Changhoon Yoo
    • Andrea Casadei-Gardini

    Original Research Article 07 September 2021 Pages: 653 - 661

    

11. Selective Inhibition of JAK1 Primes STAT5-Driven Human Leukemia Cells for ATRA-Induced Differentiation

    • Haley E. Ramsey
    • Kristy Stengel
    • Michael R. Savona

    Original Research Article 29 July 2021 Pages: 663 - 674

    

12. Isatuximab: A Review of Its Use in Multiple Myeloma

    • James E. Frampton

    Adis Drug Evaluation Open access 05 August 2021 Pages: 675 - 686

    

13. Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC

    • Yvette N. Lamb

    Adis Drug Evaluation Open access 26 September 2021 Pages: 687 - 695